Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion

被引:0
|
作者
Gebbia, V
Mauceri, G
Testa, A
Tirrito, M
Varvara, F
Cucchiara, A
Borsellino, N
Girlando, A
Ferrara, M
Caruso, F
机构
[1] Ctr Catanese Oncol, Div Med Oncol, I-95100 Catania, Italy
[2] Clin Macchiarella, Div Oncol, Palermo, Italy
[3] Clin Torina, Serv Oncol, Palermo, Italy
[4] Ctr Catanese Oncol, Div Radiotherapy, Catania, Italy
[5] Ctr Catanese Oncol, Div Surg Oncol, I-95100 Catania, Italy
关键词
breast cancer; metastases; 5-fluorouracil; levofolinic acid; vinorelbine;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Twenty-four consecutive patients with metastatic breast carcirioma (MBC) refractory to first line chemotherapy 2 were treated with high-dose folinic acid (FA) 100 mg/m(2) diluted in 250 cc of normal saline as 2 2 hour infusion followed by 5-fluorouracil (5FU) 400 mg/m(2) bolus then 5FU 600 mg/m(2) as continuous infusion for 22 hours. This therapy was repeated for 2 consecutive days. Chemotherapy was repeated every 15 days. All enrolled patients were evaluable for objective response. A complete response was achieved in 1 patient (4%) and a partial response in 6 cases (25%) for an overall response rate of 29% (confidence limits 18%-39%). The median duration of objective responses was 8.4+ months (range 3.0+/12.8). Six patients showed no change (25%) with a median duration of 4.0 months 11 patients progressed (46%). A subjective improvemernt in tumor-related symptoms was reported by all responding patients and in 3 patients with no change. Most patients (7/10) with symptomatic bone lesions had a subjective improvement with reduction in analgesic drugs consumption. Objective responses were observed at all sites of disease. In fact, responses were seen in the skin liver lung bore and rodal metastases. The median overall survival was 13.0+ months (range 4.0/16.2+). Over a total of 160 cycles (a mean of 6.6 cycles/patient) grade 1-2 leukopenia was seen in 9 patients (37%) grade 1 thrombocytoperia in 4 patients (17%) and grade 1 anemia in only 2 cases (8%). Grade 3-4 leukopenia or thrombocytopenia were not seen. Phlebitis at the injection vein occurred in 3/10 patients (30%) which refuded to implant a central line. In patients with a central line or a port-a-cath no cases of vascula toxicity were seen. Gastrointestinal toxicity was very mild with 9 patients (37%) suffering from grade 1- 2 nausea/vomiting 6 patients (25%) complaining of grade 1-2 diarrhea and 6 patients with grade 1-2 stomatitis. Hand-foot syndrome was observed in only 1 patient. No cases of grade 3-4 gastrointestinal toxicities have been, observed No cases of cardiotoxicity and/or neurotoxicity were recorded The combination of high-dose FA and 5FU given as 48 hour continuous venous infusion every 2 weeks is active, at least in. terms of objective response rate and tumor related symptoms palliation against anthracycline-refractory MBC These results compare favorably with bolus administration of FA and 5FU or other salvage regimens.
引用
收藏
页码:2289 / 2292
页数:4
相关论文
共 50 条
  • [41] Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer
    Matsumoto, Hideo
    Okumura, Hideo
    Murakami, Haruaki
    Kubota, Hisako
    Higashida, Masaharu
    Tsuruta, Atsushi
    Tohyama, Kaoru
    Hirai, Toshihiro
    ANTICANCER RESEARCH, 2015, 35 (11) : 6193 - 6199
  • [42] Continuous infusion of adriamycin plus cyclophosphamide plus 5-fluorouracil in disseminated breast cancer
    Karasyeva, V
    Zharkova, O
    Promzeleva, N
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S16 - S16
  • [43] Cardiotoxicity in 5-fluorouracil folinic acid treatment for metastatic colorectal cancer
    Käfer, G
    Achtnich, M
    Willer, A
    Weiss, A
    Queisser, W
    ONKOLOGIE, 1998, 21 (04): : 324 - 327
  • [44] A dose escalation study of leucovorin (LV) and 48-hour continuous infusion of 5-fluorouracil in combination with cyclophosphamide and vinorelbine in pretreated patients with metastatic breast cancer
    Kouroussis, C
    Kalbakis, K
    Androulakis, N
    Agelaki, S
    Vamvakas, L
    Malas, K
    Souglakos, J
    Vardakis, N
    Georgoulias, V
    ANTICANCER RESEARCH, 2004, 24 (06) : 4217 - 4221
  • [45] Phase II study of vinorelbine, epirubicin and continuous 5-fluorouracil infusion as first line treatment in anthracycline naive metastatic breast cancer.
    Berruti, A
    Bitossi, R
    Gorzegno, G
    Donadio, M
    Nigro, C
    Ardine, M
    Bertetto, O
    Bottini, A
    Danese, S
    Bertone, E
    Sarobba, MG
    Farris, A
    Bellino, R
    Katsaros, D
    Castiglione, F
    Grassi, L
    Marinone, C
    Dogliotti, L
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S91 - S91
  • [46] Mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer
    Lemmens, J
    Berteloot, P
    Thomas, J
    Wildiers, J
    Paridaens, R
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (12) : 2114 - 2115
  • [47] Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 H infusion in pretreated metastatic colorectal cancer (CRC)
    deGramont, A
    Vignoud, J
    Tournigand, C
    Louvet, C
    Varette, C
    Raymond, E
    Krulik, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 716 - 716
  • [48] EFFECTS OF THE PLASMA-CONCENTRATION OF 5-FLUOROURACIL AND THE DURATION OF CONTINUOUS VENOUS INFUSION OF 5-FLUOROURACIL WITH AN INHIBITOR OF 5-FLUOROURACIL DEGRADATION ON YOSHIDA SARCOMAS IN RATS
    FUJII, S
    SHIMAMOTO, Y
    OHSHIMO, H
    IMAOKA, T
    MOTOYAMA, M
    FUKUSHIMA, M
    SHIRASAKA, T
    JAPANESE JOURNAL OF CANCER RESEARCH, 1989, 80 (02): : 167 - 172
  • [49] PHARMACOKINETIC MODULATION OF PLASMA 5-FLUOROURACIL CONCENTRATIONS TO POTENTIATE THE ANTITUMOR-ACTIVITY OF CONTINUOUS VENOUS INFUSION OF 5-FLUOROURACIL
    FUJII, S
    FUKUSHIMA, M
    SHIMAMOTO, Y
    SHIRASAKA, T
    JAPANESE JOURNAL OF CANCER RESEARCH, 1989, 80 (06): : 509 - 512
  • [50] LONG-TERM CONTINUOUS 5-FLUOROURACIL (5-FU) INFUSION IN THE TREATMENT OF FAR ADVANCED METASTATIC BREAST-CARCINOMA
    HATFIELD, AK
    JOHNSON, PA
    EGNER, JR
    LONG, CA
    BREAST CANCER RESEARCH AND TREATMENT, 1987, 10 (01) : 109 - 109